Clinical trials: Patients With Acute Myeloid Leukemia
AML With Monocytic Differentiation, CMML
IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML
To assess safety and tolerability at increasing dose levels of IO-202 in successive cohorts of participants with AML with monocytic differentiation and CMML in order to estimate the maximum tolerated dose (MTD) or maximum…
- Trial name
- NCT04372433
- Testing
- IO-202, IO-202 and Azacitidine, IO-202 and Azacitidine + Venetoclax
- Where
- 14 sites in United States
- Volunteers
- 67 people
- Sponsor
- Immune-Onc Therapeutics
Acute Myeloid Leukemia
Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)
The Phase 1 portion of this study is a single-arm, open-label, multicenter, non-randomized interventional study to evaluate the pharmacokinetic (PK) interaction, safety, and efficacy of ASTX727 when given in combination with…
- Trial name
- NCT04657081
- Testing
- Decitabine and Cedazuridine (ASTX727), Venetoclax
- Where
- 34 sites in United States, Canada and 1 more
- Volunteers
- 101 people
- Sponsor
- Taiho Oncology, Inc.
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome With Laromustine and Infusional Cytarabine
The purpose of the Phase I portion of this study is to evaluate the safety of this combination of medications and to determine the appropriate dose of VNP40101M to be used in combination with infusional cytarabine (araC) in…
- Trial name
- NCT00655395
- Testing
- Laromustine (VNP40101M) and Ara-C
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Viron Therapeutics Inc
Acute Myeloid Leukemia, Myelodysplastic Syndromes
A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes
Study GLB-001-01 is a first-in-human (FIH), Phase 1, open-label, dose escalation and expansion clinical study of GLB-001 in participants with relapsed or refractory acute myeloid leukemia (R/R AML) or in participants with…
- Trial name
- NCT06146257
- Testing
- GLB-001
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- GluBio Therapeutics Inc.
Secondary AML, Myelofibrosis
A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis
The purpose of this study is to test the safest and most effective dose of a new investigational drug, rebecsinib. Participants in this study will have either Secondary Acute Myeloid Leukemia (sAML) that has either returned…
- Trial name
- NCT07250646
- Testing
- rebecsinib
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Aspera Biomedicines, Inc.
Advanced Cancer, Solid Tumors
A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML
This research study is being done in people with advanced-stage solid tumor cancer. Advanced stage solid tumor cancer is a cancer that forms an abnormal mass of tissue that usually does not contain cysts or liquid areas.
- Conditions
- Advanced Cancer, Solid Tumors, Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse
- Trial name
- NCT03690154
- Testing
- FN-1501
- Where
- 3 sites in United States, Australia
- Volunteers
- 67 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia
A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)
The primary objective of this study is to evaluate the safety of lanraplenib (LANRA) in combination with the FMS-like tyrosine kinase 3 (FLT3) inhibitor gilteritinib, in participants with relapsed or refractory (R/R) FLT3-mutated…
- Conditions
- Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Trial name
- NCT05028751
- Testing
- Lanraplenib, Gilteritinib
- Where
- 17 sites in United States, Spain
- Volunteers
- 24 people
- Sponsor
- Kronos Bio
Leukemia, Myelocytic, Acute
Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular Remission
The study will compare the efficacy of the 2 treatments in intermediate and high-risk APL patients in achieving first hematological complete remission and molecular remission.
- Trial name
- NCT00962767
- Testing
- gemtuzumab ozogamicin, ATRA plus 6-MP and MTX
- Volunteers
- 168 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Hematological Malignancies, Acute Lymphoblastic Leukemia (ALL)
Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS
This study is an open-label, controlled, multicenter, international, Phase III, randomized study of transplantation of NiCord® versus transplantation of one or two unmanipulated, unrelated cord blood units in patients with acute…
- Conditions
- Hematological Malignancies, Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia (CML)
- Trial name
- NCT02730299
- Testing
- NiCord® (omidubicel), Cord Blood Unit
- Where
- 52 sites in United States, Brazil and 8 more
- Volunteers
- 125 people
- Sponsor
- Gamida Cell ltd
High Risk Acute Myeloid Leukemia
Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia
To confirm the efficacy of CPX-351 compared to 7+3 as first line therapy in elderly patients (60-75 yrs) with high risk (secondary) Acute Myeloid Leukemia. The primary efficacy endpoint will be overall survival.
- Trial name
- 301 (NCT01696084)
- Testing
- CPX-351, 7+3 (cytarabine and daunorubicin)
- Where
- 43 sites in United States, Canada
- Volunteers
- 309 people
- Sponsor
- Jazz Pharmaceuticals
Acute Myeloid Leukemia, Relapsed, Adult
A Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Very Low-dose Cytarabine in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation
Phase I, open label, non-randomized, multicenter, prospective dose escalation study of F16IL2 in combination with very low-dose cytarabine in subjects with acute myeloid leukemia relapse after allogeneic hematopoietic stem cell…
- Trial name
- NCT02957032
- Testing
- F16IL2, cytarabine
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Philogen S.p.A.
Leukemia
A Study to Investigate BAY2402234, a Dihydroorotate Dehydrogenase (DHODH) Inhibitor, in Myeloid Malignancies
The primary objective is to determine the safety, tolerability, pharmacokinetics, maximum tolerated dose (MTD), or pharmacological active dose (PAD) of BAY2402234 in patients with acute myeloid leukemia (AML), myelodysplastic…
- Trial name
- NCT03404726
- Testing
- BAY2402234
- Where
- 5 sites in United States, France
- Volunteers
- 40 people
- Sponsor
- Bayer
Leukemia
VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy, such as VNP40101M and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00354276
- Testing
- cytarabine, laromustine
- Where
- 3 sites in United States, France and 1 more
- Volunteers
- 85 people
- Sponsor
- Vion Pharmaceuticals
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
This is a multicenter, open-label, Phase 1/2a dose escalation and expansion study of orally administered emavusertib (CA-4948) monotherapy in adult patients with AML or higher- risk Myelodysplastic Syndrome (hrMDS).
- Trial name
- NCT04278768
- Testing
- Emavusertib, Venetoclax
- Where
- 32 sites in United States, Czechia and 6 more
- Volunteers
- 366 people
- Sponsor
- Curis, Inc.
Acute Myeloid Leukemia
Using Gilteritinib to Keep People With Acute Myeloid Leukemia Cancer-free After a Stem Cell Transplant
People with acute myeloid leukemia (AML) are usually treated with chemotherapy. When the cancer comes back (relapse) the next treatment is usually a stem cell transplant.
- Trial name
- NCT06734585
- Testing
- Gilteritinib
- Where
- 18 sites in Australia, Brazil and 4 more
- Volunteers
- 114 people
- Sponsor
- Astellas Pharma Singapore Pte. Ltd.
Leukemia
AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen
To determine if AEG35156 can enhance the combined complete remission (CR) and CR with incomplete platelet recovery (CRp) rate of high-dose cytarabine and idarubicin in AML following failure of a single standard dose cytarabine…
- Trial name
- NCT01018069
- Testing
- AEG35156
- Where
- 18 sites in United States, Canada and 1 more
- Volunteers
- 60 people
- Sponsor
- Aegera Therapeutics
Acute Myeloid Leukemia
Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 in Acute Myelogenous Leukemia (AML) Patients
The purpose of this open label study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of AZD1208 in patients with recurrent or refractory Acute Myelogenous Leukemia (AML). This study will have two parts.
- Trial name
- NCT01489722
- Testing
- AZD1208
- Where
- 4 sites in United States, Canada
- Volunteers
- 55 people
- Sponsor
- AstraZeneca
Acute Myeloid Leukemia, Relapsed AML
Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia
This dose-escalating phase I trial assesses for the first time the safety, the side effects and the harmlessness, as well as the therapeutical benefit of the new study drug GEM333 in patients with acute myeloid leukemia (AML).
- Conditions
- Acute Myeloid Leukemia, Relapsed AML, Refractory AML
- Trial name
- NCT03516760
- Testing
- GEM333
- Where
- 7 sites in Germany
- Volunteers
- 36 people
- Sponsor
- AvenCell Europe GmbH
Acute Myeloid Leukemia
A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)
This study is a Phase 1, open-label, dose escalation, and cohort expansion study designed to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary anti-leukemic activity of…
- Trial name
- NCT05470140
- Testing
- WU-NK-101
- Where
- 9 sites in United States, Australia
- Volunteers
- 9 people
- Sponsor
- Allotera Therapeutics
Acute Myelogenous Leukemia
Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)
The purpose of the Phase 1b dose finding phase is to determine the safety, tolerability, and maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of TAK-659 in participants with relapsed or refractory AML.
- Trial name
- NCT02323113
- Testing
- TAK-659
- Where
- 17 sites in United States, Canada
- Volunteers
- 43 people
- Sponsor
- Calithera Biosciences, Inc